Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Discovery of Small Molecules for Fluorescent Detection of Complement Activation Product C3d.

Gorham RD Jr, Nuñez V, Lin JH, Rooijakkers SH, Vullev VI, Morikis D.

J Med Chem. 2015 Dec 24;58(24):9535-45. doi: 10.1021/acs.jmedchem.5b01062. Epub 2015 Dec 9.

PMID:
26613117
2.

Endosidin2 targets conserved exocyst complex subunit EXO70 to inhibit exocytosis.

Zhang C, Brown MQ, van de Ven W, Zhang ZM, Wu B, Young MC, Synek L, Borchardt D, Harrison R, Pan S, Luo N, Huang YM, Ghang YJ, Ung N, Li R, Isley J, Morikis D, Song J, Guo W, Hooley RJ, Chang CE, Yang Z, Zarsky V, Muday GK, Hicks GR, Raikhel NV.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):E41-50. doi: 10.1073/pnas.1521248112. Epub 2015 Nov 25.

3.

Electrostatic Interactions between Complement Regulator CD46(SCR1-2) and Adenovirus Ad11/Ad21 Fiber Protein Knob.

Chen CZ, Gorham RD Jr, Gaieb Z, Morikis D.

Mol Biol Int. 2015;2015:967465. doi: 10.1155/2015/967465. Epub 2015 Aug 19.

4.

Hybrid flagellin as a T cell independent vaccine scaffold.

Bennett KM, Gorham RD Jr, Gusti V, Trinh L, Morikis D, Lo DD.

BMC Biotechnol. 2015 Aug 12;15:71. doi: 10.1186/s12896-015-0194-0.

5.

Energetic evaluation of binding modes in the C3d and Factor H (CCP 19-20) complex.

E S Harrison R, Gorham RD Jr, Morikis D.

Protein Sci. 2015 May;24(5):789-802. doi: 10.1002/pro.2650. Epub 2015 Mar 11.

PMID:
25628052
6.

New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics.

Gorham RD Jr, Forest DL, Khoury GA, Smadbeck J, Beecher CN, Healy ED, Tamamis P, Archontis G, Larive CK, Floudas CA, Radeke MJ, Johnson LV, Morikis D.

J Med Chem. 2015 Jan 22;58(2):814-26. doi: 10.1021/jm501345y. Epub 2014 Dec 29.

7.

Derivation of ligands for the complement C3a receptor from the C-terminus of C5a.

Halai R, Bellows-Peterson ML, Branchett W, Smadbeck J, Kieslich CA, Croker DE, Cooper MA, Morikis D, Woodruff TM, Floudas CA, Monk PN.

Eur J Pharmacol. 2014 Dec 15;745:176-81. doi: 10.1016/j.ejphar.2014.10.041. Epub 2014 Oct 30.

8.

A theoretical view of the C3d:CR2 binding controversy.

Mohan RR, Gorham RD Jr, Morikis D.

Mol Immunol. 2015 Mar;64(1):112-22. doi: 10.1016/j.molimm.2014.11.006. Epub 2014 Nov 27.

PMID:
25433434
9.

Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking.

Tamamis P, Kieslich CA, Nikiforovich GV, Woodruff TM, Morikis D, Archontis G.

BMC Biophys. 2014 Aug 12;7:5. doi: 10.1186/2046-1682-7-5. eCollection 2014.

10.

Viral regulators of complement activation: structure, function and evolution.

Ojha H, Panwar HS, Gorham RD Jr, Morikis D, Sahu A.

Mol Immunol. 2014 Oct;61(2):89-99. doi: 10.1016/j.molimm.2014.06.004. Epub 2014 Jun 27. Review.

PMID:
24976595
11.

Engineering pre-SUMO4 as efficient substrate of SENP2.

Liu Y, Kieslich CA, Morikis D, Liao J.

Protein Eng Des Sel. 2014 Apr;27(4):117-26. doi: 10.1093/protein/gzu004.

12.

Molecular analysis of the interaction between staphylococcal virulence factor Sbi-IV and complement C3d.

Gorham RD Jr, Rodriguez W, Morikis D.

Biophys J. 2014 Mar 4;106(5):1164-73. doi: 10.1016/j.bpj.2014.01.033.

13.

Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures.

Gorham RD Jr, Forest DL, Tamamis P, López de Victoria A, Kraszni M, Kieslich CA, Banna CD, Bellows-Peterson ML, Larive CK, Floudas CA, Archontis G, Johnson LV, Morikis D.

Exp Eye Res. 2013 Nov;116:96-108. doi: 10.1016/j.exer.2013.07.023. Epub 2013 Aug 15.

14.

A predictive model for HIV type 1 coreceptor selectivity.

Kieslich CA, Shin D, López de Victoria A, González-Rivera G, Morikis D.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1386-94. doi: 10.1089/AID.2012.0173. Epub 2013 Jul 30.

PMID:
23808984
15.

The two sides of complement C3d: evolution of electrostatics in a link between innate and adaptive immunity.

Kieslich CA, Morikis D.

PLoS Comput Biol. 2012;8(12):e1002840. doi: 10.1371/journal.pcbi.1002840. Epub 2012 Dec 27.

16.

Insights into the structure, correlated motions, and electrostatic properties of two HIV-1 gp120 V3 loops.

López de Victoria A, Tamamis P, Kieslich CA, Morikis D.

PLoS One. 2012;7(11):e49925. doi: 10.1371/journal.pone.0049925. Epub 2012 Nov 19.

17.

De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation.

Bellows-Peterson ML, Fung HK, Floudas CA, Kieslich CA, Zhang L, Morikis D, Wareham KJ, Monk PN, Hawksworth OA, Woodruff TM.

J Med Chem. 2012 May 10;55(9):4159-68. doi: 10.1021/jm201609k. Epub 2012 Apr 20.

18.

Clustering of HIV-1 Subtypes Based on gp120 V3 Loop electrostatic properties.

López de Victoria A, Kieslich CA, Rizos AK, Krambovitis E, Morikis D.

BMC Biophys. 2012 Feb 7;5:3. doi: 10.1186/2046-1682-5-3.

19.

Molecular dynamics in drug design: new generations of compstatin analogs.

Tamamis P, López de Victoria A, Gorham RD Jr, Bellows-Peterson ML, Pierou P, Floudas CA, Morikis D, Archontis G.

Chem Biol Drug Des. 2012 May;79(5):703-18. doi: 10.1111/j.1747-0285.2012.01324.x. Epub 2012 Feb 9.

20.

Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin.

Tamamis P, Pierou P, Mytidou C, Floudas CA, Morikis D, Archontis G.

Proteins. 2011 Nov;79(11):3166-79. doi: 10.1002/prot.23149. Epub 2011 Aug 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk